Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Tetrylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrylammonium SCHEMBL28600427 | 1.00 | TSHR (0.80) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL283360 | 1.00 | TSHR (0.80) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL9292825 | 1.00 | TSHR (0.80) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL28600737 | 0.95 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL28768609 | 0.95 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL3722218 | 0.95 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL1035999 | 0.95 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL7740433 | 0.95 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL10887 | 0.95 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL5142182 | 0.95 | TSHR (0.89) | TSHRNFKB1KCNA1KDM4EPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113735880-B | Preparation method of everolimus and intermediate thereof | 鲁南制药集团股份有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-114716296-B | Efficient halogenation synthesis method of alkyl halide | 润药仁智(北京)科技有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-114716296-A | Efficient halogenation synthesis method of alkyl halide | 北京大学 | 2022-07-08 | — | — | CN | claimed |
| CN-109438397-B | Synthetic method of sofosbuvir intermediate | 江苏科本药业有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-113735880-A | Preparation method of everolimus and intermediate thereof | 鲁南制药集团股份有限公司 | 2021-12-03 | — | — | CN | claimed |
| WO-2025121238-A1 | METHOD FOR PRODUCING AROMATIC POLYSULFONE | 住友化学株式会社 | 2025-06-12 | — | — | WO | disclosed |
| CN-119528872-A | Synthesis method of additive fluoroethylene carbonate for lithium battery electrolyte | 苏州华一新能源科技股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240382477-A1 | NITROGEN-CONTAINING HETEROCYCLIC PYRIDINE COMPOUND | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| US-12071395-B2 | Method for producing carbodiimide compound | NISSHINBO CHEMICAL INC. (JP) | 2024-08-27 | — | — | US | disclosed |
| US-12017977-B2 | Method for producing carbodiimide compound | NISSHINBO CHEMICAL INC. (JP) | 2024-06-25 | — | — | US | disclosed |
| EP-4335440-A1 | NITROGEN-CONTAINING HETEROCYCLIC PYRIDINE COMPOUND | Shanghai Zheye Biotechnology Co., Ltd. (CN) | 2024-03-13 | — | — | EP | disclosed |
| CN-113735880-B | Preparation method of everolimus and intermediate thereof | 鲁南制药集团股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-4692540-A | Process for the preparation of cyclic phosphites | CIBA-GEIGY CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0159294-A2 | Process for preparing cyclic phosphorous-acid esters | CIBA-GEIGY AG (CH) | 1985-10-23 | — | — | EP | disclosed |
| US-4539148-A | OXYGENATED BUTYRIC ACID DERIVATIVES OF OXOAZETIDINE | SHIONOGI & CO., LTD. (JP) | 1985-09-03 | — | — | US | disclosed |
| EP-0137794-A1 | CLAVAM DERIVATIVES | BEECHAM GROUP PLC (GB) | 1985-04-24 | — | — | EP | disclosed |
| WO-1984003282-A1 | CLAVAM DERIVATIVES | BEECHAM GROUP PLC (GB) | 1984-08-30 | — | — | WO | disclosed |
| US-4464299-A | Antibacterial carbapenem compounds | SHIONOGI & CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4459290-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1984-07-10 | — | — | US | disclosed |
| EP-0102893-A1 | A novel production of 1-oxacephams | SHIONOGI & CO., LTD. (JP) | 1984-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382477-A1 | NITROGEN-CONTAINING HETEROCYCLIC PYRIDINE COMPOUND | NNMT, NOD1, NOD2 | TSHR 3343/4885NFKB1 95/4885KCNA1 4393/4885 |
| US-12071395-B2 | Method for producing carbodiimide compound | IDH2, IDH3A, IDH1 | TSHR 3990/4885NFKB1 2240/4885KCNA1 1689/4885 |
| US-12017977-B2 | Method for producing carbodiimide compound | CA9, CA4, CA14 | TSHR 3459/4885NFKB1 2506/4885KCNA1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.